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Background
Obtaining quantitative measures on the clinician's habits
for using anti-manic drugs, and analyzing the stability of
primary treatment choice.
Materials and methods
In March 2003, 110 psychiatrists were selected to be rep-
resentative at a national level in France. Each investigator
should include 3 consecutive patients presenting acutely
at least 2 manic symptoms. A structured file was designed
to collect precise information on drug prescriptions dur-
ing a 6-month prospective follow-up (at inclusion, D15,
D30, D60, D90, and D180).
Population: 286 patients with acute manic symptoms
(61.2% primary bipolars and 30.4% psychotics) were
included and 90.6% completed the study. At inclusion,
Mood-stabilizers (MS) were choused as primary treatment
in 63.3% of cases (32.9% divalproate, 14.3% lithium,
9.4% valpromide, 4.6% carbamazepine), and anti- psy-
chotics (AP) in 26.6% (10.8% olanzapine, 3.1% haloperi-
dol, 2.8 risperidone).
Results
At the end of follow-up, we observed a global stability for
diagnosis in 93% of patients and for the choice of primary
anti-manic drug therapy in 74%. In case of changing pri-
mary treatment, almost half of changes were done within
the same drug family and half toward a switch to another
family. At D180, the switch rate from MS to AP was 5%
and from AP to MS 14.5%. The global rate of treatment
modifications (including changing of dose) was 44% at
D15, 42% at D30, 34% at D60, 35% at D90, 32% at
D180, and the major reason for modifications was partial
efficacy (respectively 17.5%, 15%, 9.4%, 12.2% and
9.4%). Intolerance was the second reason (respectively
8%, 6.3%, 7%, 4.2% and 3.8%).
Discussion
The data suggested the global stability of diagnosis in
patients presenting with acute manic symptoms and also
the stability of primary drug therapy choice.
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